ReviewNeuroscience letters2019
PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases.
Review in Neuroscience letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04634994 (Novel Assessment of Synaptic Density in Progressive MS), which is not on this map. Cited by 86 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Novel Assessment of Synaptic Density in Progressive MS
Who cites it
86 citing papers in PubMed, 3 syntheses or guidelines pooled it, 126 citations in OpenAlex.
- Pooled it
- Alterations in brain synaptic proteins and mRNAs in mood disorders: a systematic review and meta-analysis of postmortem brain studies.Molecular psychiatry · 2022Pooled it
- Transfer Learning for Alzheimer's Disease through Neuroimaging Biomarkers: A Systematic Review.Sensors (Basel, Switzerland) · 2021Pooled it
- Association of Brain Atrophy With Functional Outcome and Recovery Trajectories After Thrombectomy: Post Hoc Analysis of the ESCAPE-NA1 Trial.Neurology · 2023Trial
- Left Cerebellar-Right Frontal Uncoupling in Female First-Episode Major Depressive Disorder: Synaptic Evidence From [CNS neuroscience & therapeutics · 2026Article
- Impact of brain frailty on language recovery in patients with acute post-stroke aphasia: a post-hoc analysis of the LEXI randomized controlled trial.Neurological research and practice · 2026Article
- Fully Automated Azeotropic Drying-Free Synthesis of [Molecules (Basel, Switzerland) · 2026Article
- Synaptic Plasticity-Intrinsic Excitability and Antidepressant Discovery.Biomedicines · 2026Review
- Noninvasive Quantification of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- In Vivo Positron Emission Tomography Imaging of Presynaptic Density Reveals Stress-Associated Synaptic Deficits Related to Behavioral and Molecular Alterations in Rats.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2026Article
- SV2A PET reveals synaptic density loss in experimental autoimmune encephalomyelitis and in a pilot multiple sclerosis study.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Direct evidence for synaptic density changes in tinnitus:European journal of nuclear medicine and molecular imaging · 2026Article
- HIV-1 Tat expression drives progressive synaptic decline: evidence from longitudinal [NeuroImmune pharmacology and therapeutics · 2026Article
- Translational molecular imaging and drug development in multiple sclerosis.Theranostics · 2026Review
- Longitudinal biomarker studies in human neuroimaging: capturing biological change of Alzheimer's pathology.Alzheimer's research & therapy · 2025Review
- Translating Alzheimer's Disease Mechanisms into Therapeutic Opportunities.Biomolecules · 2025Review
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- The Future of PET Imaging in Multiple Sclerosis: Characterisation of Individual White Matter Lesions.Journal of clinical medicine · 2025Review
- Article
- bFGF-Chitosan "brain glue" promotes functional recovery after cortical ischemic stroke.Bioactive materials · 2025Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Synaptic vesicle glycoprotein 2A (SV2A) is expressed ubiquitously in neurons of the central nervous system, and is the binding target of the anti-epileptic drug levetiracetam. Because of the availability of positron emission tomography (PET) ligands targeting SV2A, there is increasing enthusiasm on the use of SV2A PET to study a variety of neuropsychiatric diseases. This review discusses the recent development of radioligands for PET imaging of SV2A and their potential use in the research and diagnosis of CNS diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.